Michael Lehmicke, Senior Director of Science & Industry Affairs, Alliance for Regenerative Medicine, Washington, D.C., provides an overview of how the cell and gene therapy (GCT) industry has adapted to the COVID-19 pandemic. Overall, the industry has shown resilience to the pandemic, with clinical trials successfully adapting to the change in circumstances. The advent of remote working has additionally increased the pool of available workers, and remote inspections by regulatory authorities may positively impact the regulatory process. This interview took place at Advanced Therapies Week 2022.
Michael Lehmicke is the Senior Director of Science & Industry Affairs at Alliance for Regenerative Medicine.